首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1623070

全球抗感染藥物市場規模：依產品、給藥途徑、應用、最終用戶和地區劃分，2024-2031年

Global Anti-Infective Agents Market Size By Product, Route of Administration, By Application, End-Users, And Region for 2024-2031

出版日期: 2024年10月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

抗感染市場評估，2024-2031

伊波拉和瘧疾等傳染病流行率的上升以及公眾意識的提高等因素是推動全球抗感染藥物市場成長的一些因素。Verified Market Research分析師預計，到2031年，抗感染藥物市場估值將達到1,780.1億美元，低於2023年1,397.5億美元的收入。

隨著世界人口老化的增加，由於感染性疾病的易感性增加，對抗感染藥物等藥物的需求迅速增加。需求激增將推動市場從2024年到2031年複合年增長率為2.02%。

抗感染市場定義/概述

抗感染藥物是指用於預防、治療和對抗多種病原體（包括細菌、病毒、真菌和寄生蟲）引起的感染的一大類藥物和物質。這些藥物包括多種藥物，包括抗生素、抗病毒藥物、抗真菌藥物、抗菌藥物、疫苗和免疫療法。抗感染藥物的主要作用是抑製或殺死感染性細菌的生長，控製或根除感染，恢復感染者的健康。抗感染藥物透過控制感染、預防疫情和減少病原體在社區中的傳播，在現代醫學和公共衛生中發揮重要作用。

抗感染藥物還可以徹底殺死感染微生物。抗感染藥包括抗黴菌藥、驅蟲藥、抗瘧藥、抗結核藥、抗病毒藥和抗寄生蟲藥。美國食品藥物管理局 (FDA) 已批准多種不同類型的藥物，包括用於治療 HIV-1 感染的 Descovy 和用於治療成人慢性丙型肝炎病毒 (HCV) 基因型 1 或 4 感染的 Zepaty。

推動抗感染藥物市場發展的因素有哪些？

細菌、病毒、真菌和寄生蟲感染等傳染病在全球範圍內不斷增加，增加了對抗感染藥物的需求。人口增長、都市化、旅行和氣候變遷等因素導致傳染病的傳播，需要有效的治療來限制傳播。抗藥性病原體的出現，通常稱為抗菌素抗藥性（AMR），對全球公共衛生構成重大威脅。目前的治療方法無法應對細菌、病毒、真菌和寄生蟲的抗藥性菌株，這增加了對能夠克服抗藥性機制並對抗多重抗藥性感染的新型創新抗感染藥物的需求，並正在推動抗感染藥物的成長。因此，COVID-19、愛滋病毒/愛滋病等傳染病以及登革熱和瘧疾等媒介傳播疾病的出現和重新出現阻礙了有效抗感染藥物的開發和供應。

隨著治療和程序變得更加複雜，包括手術、移植和免疫抑制治療，治療相關感染 (HAI) 的風險也會增加。因此，抗感染藥物在 HAI 的預防和治療、降低併發症的發生率、改善患者的醫療預後方面發揮著重要作用。公共衛生措施、教育活動和意識計劃宣傳了疫苗接種、手部衛生和抗生素治療等感染預防和控制措施的重要性。這些努力正在促進抗生素的使用，作為減輕傳染病負擔和保護公眾健康的綜合策略的一部分。

此外，新興國家可支配收入的增加和政府措施可能會導致醫療保健支出增加，從而導致抗感染藥物的需求增加。同樣，對藥物發現、基因組學、聯合治療和個人化醫療的投資增加，正在導致更有針對性、更有效、副作用更少的抗感染藥物的開發。

抗感染市場面臨哪些課題？

抗感染市場最重要的課題之一是對抗生素產生抗藥性的病原體的出現和傳播。抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥物的過度使用和過度使用導致了抗藥性菌株的出現，儘管迫切需要新的抗感染藥物，但現有的治療方法卻使法律效力降低，限制了傳染病的治療。抗生素開發管道相對較小。由於抗生素成本高、開發時間長且商業回報不確定，許多製藥公司正在減少對抗生素的投資。結果，新的抗生素和其他抗感染藥物無法進入市場，加劇了抗菌素抗藥性問題。

新型抗感染藥物（尤其是藥物）的監管審批過程漫長、複雜且耗費資源。特別是針對多重抗藥性病原體和新興傳染病的藥物需要經過長期而複雜的努力才能獲得批准。監管機構需要大量的臨床數據來證明安全性、有效性和藥物動力學，特別是在抗菌功效的替代物或生物標記尚未確定的情況下，可能會延遲進入市場。經濟因素，包括定價壓力、報銷實踐和市場動態，對開發傳染病治療和商業化的公司提出了課題。仿製藥抗生素的低廉價格以及臨床開發和監管合規的高昂成本阻礙了製藥公司投資新抗生素，尤其是針對特定適應症或小型患者群體的抗生素。

在資源有限的環境中，取得抗感染藥物往往受到限制，特別是在衛生基礎設施薄弱的低收入和中等收入國家。在其他情況下，診斷和治療方案可能不足。抗生素成本高昂、衛生服務缺乏以及分銷和供應鏈管理方面的課題進一步阻礙了這些地區獲得有效的傳染病治療。

The rising prevalence of infectious diseases such as Ebola and malaria along with other factors such as growing awareness among the commoners are some of the factors that are driving the growth of the global anti-infective agents market. According to the analyst from Verified Market Research, the Anti-infective Agents Market is estimated to reach a valuation of USD 178.01 Billion by 2031 by subjugating the revenue of USD 139.75 Billion in 2023.

As the geriatric population grows globally, the requirement of medications like anti-infective agents spurs due to their higher susceptibility to infections. This surge in demand enables the market to grow at aCAGR of 2.02% from 2024 to 2031.

Anti-Infective Agents Market: Definition/ Overview

Anti-infective agents refer to a broad category of medications or substances used to prevent, treat, or combat infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These agents encompass a diverse range of pharmaceuticals, including antibiotics, antivirals, antifungals, and antiphrastic drugs, as well as vaccines and immunotherapies. Their primary function is to inhibit the growth or kill the infectious organisms, thereby controlling or eradicating the infection and restoring health to the affected individual. Anti-infective agents play a critical role in modern medicine and public health by helping to manage infectious diseases, prevent outbreaks, and reduce the spread of pathogens within communities.

The anti-infective agents can also kill the infectious organism outright. The anti-infective group consists of antifungals, anthelmintics, anthelmintics, antimalarials, antituberculosis agents, antivirals, and antiprotozoals. The Food and Drug Administration (FDA) approved various types of drugs such as Descovy for the treatment of HIV-1 infection and Zepatier that target the chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Anti-Infective Agents Market?

The global increase in infectious diseases, including bacterial, viral, fungal, and parasitic infections, is increasing the demand for anti-infective agents. Factors such as population growth, urbanization, travel, and climate change contribute to the spread of infectious diseases that require effective treatment to control the spread of infection. The emergence of drug-resistant pathogens, commonly known as antimicrobial resistance (AMR), poses a major threat to public health worldwide. As current treatments fail against resistant strains of bacteria, viruses, fungi, and parasites, there is a growing need for new and innovative anti-infective agents that can overcome resistance mechanisms and combat multidrug-resistant infections, thereby, boosting the growth of the anti-infective agents market. Consequently, the emergence and re-emergence of infectious diseases like COVID-19, HIV/AIDS, and vector-borne infections like dengue and malaria necessitate the development and availability of effective anti-infective agents to combat them.

The increasing complexity of medicine and procedures, including surgery, transplantation, and immunosuppressive therapy, increases the risk of treatment-associated infections (HAIs). Thus, anti-infective agents play an important role in preventing and treating HAIs, reducing the incidence of complications, and improving patient outcomes in healthcare. Public health initiatives, educational campaigns, and awareness programs promote the importance of infection prevention and control measures, including vaccination, hand hygiene, and antimicrobial treatment. These efforts promote the use of antimicrobial agents as part of comprehensive strategies to reduce the burden of infectious diseases and protect public health.

Also, growing disposable income and government initiatives in emerging countries are leading to rise in healthcare spending, potentially leading to higher demand for anti-infective agents. Similarly, rise in investment on drug discovery, genomics, combination therapies, and personalized medicine are leading to the development of more targeted and effective anti-infective agents with fewer side effects.

What are the Challenges in Anti-infective Agents Market?

One of the most important challenges in the anti-infective market is the emergence and spread of pathogens resistant to antimicrobials. The excessive use and abuse of antibiotics, antivirals, antifungals, and anti-parasitic contribute to the emergence of drug-resistant strains, making existing treatments less effective and limiting treatment for infectious diseases despite the urgent need for new anti-infective agents, the pharmaceutical. The antimicrobial development pipeline is relatively small. Many pharmaceutical companies have reduced their investments in antimicrobial RandD drugs due to the high costs, long development timelines, and uncertain commercial returns of these therapies. As a result, there are no new antibiotics or other anti-infective agents on the market, exacerbating the problem of antimicrobial resistance.

Regulatory approval processes for new anti-infective agents can be long, complex, and resource intensive, especially for drugs. That targets multidrug-resistant pathogens or emerging infectious diseases. Regulatory agencies require extensive clinical data demonstrating safety, efficacy, and pharmacokinetics, which can delay approval and market entry of new therapies, particularly in the absence of defined surrogates or biomarkers of antimicrobial efficacy. Economic considerations, including pricing pressures, reimbursement practices, and market dynamics, present challenges to companies that develop and commercialize infectious agents. The low prices of generic antibiotics and the high costs of clinical development and regulatory compliance prevent pharmaceutical companies from investing in new antimicrobials, especially those targeting specific indications or small patient populations.

Availability of anti-infectives is often limited in resource-constrained settings, especially in low and middle-income countries with poor health infrastructure. , diagnostic options, and treatment options may be inadequate. The high cost of proprietary antimicrobials, lack of health services, and problems with distribution and supply chain management further impede access to effective infectious disease treatments in these regions.

Category-Wise Acumens

Which Product Segment is Projected to Hold a Major Share in the Market?

The antibacterial segment is anticipated to hold almost 50% share in the anti-infective agents market. This dominance of antibacterial agents is primarily due to their increasing use to treat a broad spectrum of bacterial infections, right from common respiratory infections to life-threatening conditions like pneumonia and sepsis. In the majority of cases, bacterial infections are proven to be a common cause of illnesses, propelling demand for antibacterial agents for prevention and treatment.

Ongoing research and development in the field of antibacterial drug discovery or therapies along with the presence of prominent drug manufacturers developing new antibiotics to treat infections is projected to bolster the sales of antibacterial agents over the coming years. However, the rise of antimicrobial resistance is a growing concern, necessitating the development of novel anti-infective agents across all categories to combat various types of infections.

While the antibacterial segment is estimated to hold a major share of the market, the antiviral segment is anticipated to exhibit rapid growth over the forecast period after the emergence of the COVID-19 pandemic.

Will Demand for Easy Administration Increase Sales of Oral Anti-Infective Agents?

The oral administration is currently holding the leading position in the route of administration segment within the anti-infective agents market during the forecast period. The convenience for administration in patients compared to other routes, including injection or inhalation, is surging demand for oral administration. Also, the need for improved medical adherence and efficient treatment outcomes creates lucrative opportunities for oral medications.

Additionally, the cost-effectiveness is projected to increase its accessibility for patients and healthcare systems.

Besides, the availability of a vast array of anti-infective agents in oral formulations, catering to the treatment of various infections across different patient populations is a market growth booster.

Country/Region-wise Acumens

Which Region has most potential for growth of Anti-infective Agents Market?

Asia-Pacific has a huge and diversified population, resulting in differing degrees of healthcare access and infrastructure. The region has a high incidence of infectious illnesses, such as respiratory infections, diarrheal diseases, vector-borne diseases, and new infectious threats including antimicrobial-resistant infections. Infectious disorders are prevalent in the region, driving the demand for effective anti-infective medications. Many Asia-Pacific countries are experiencing economic growth and development, which is driving up healthcare spending and infrastructure investment. Rising affluence, urbanization, and government measures to promote healthcare access all contribute to increased demand for healthcare services, such as anti-infective medicines. Emerging economies in Asia-Pacific, including China, India, Indonesia, and Vietnam, provide considerable growth potential for pharmaceutical businesses and healthcare services.

This region has antimicrobial resistance (AMR) concerns as a result of extensive antibiotic usage, insufficient infection control measures, and restricted access to healthcare services. Addressing antimicrobial resistance necessitates collaborative efforts to encourage antimicrobial stewardship, surveillance, and research, resulting in an increased need for new and novel anti-infective drugs in the area. Governments in the Asia-Pacific region are launching steps to enhance healthcare systems, increase access to medications, and address public health concerns, especially infectious illnesses. Public-private collaborations, legislative changes, and investment incentives are all helping fund anti-infective agent research and development, promoting innovation and market expansion.

Which Region Dominates in Anti-Infective Agents Market?

North American healthcare systems and infrastructure are among the most sophisticated in the world. The region is home to prominent pharmaceutical businesses, research organizations, and healthcare facilities focused on infectious disease management and treatment. The availability of cutting-edge medical facilities and experience helps to accelerate the research, manufacture, and uptake of anti-infective medications.

North American government is making large investments in pharmaceutical and healthcare research and development (R&D). The presence of prestigious academic institutions, government-funded research organizations, and private-sector R&D facilities accelerated the discovery and development of novel anti-infective agents. The region's powerful R&D environment helps scientists to translate their findings into clinically useful therapies. The regulatory framework in North America, notably in the United States, supports pharmaceutical discovery and commercialization.

Despite its modern healthcare system, North America continues to confront difficulties from infectious illnesses and antibiotic resistance. The region bears a heavy burden of healthcare-associated diseases, community-acquired illnesses, and new infectious threats. Antimicrobial resistance is becoming a major problem, demanding the development of new anti-infective medicines with novel modes of action and increased efficacy. Many of the world's largest pharmaceutical firms conduct research, development, production, and marketing of anti-infective drugs in North America. These firms use their scientific knowledge, financial resources, and worldwide networks to spur innovation and fulfill unmet medical needs in infectious disease treatment. The existence of a robust pharmaceutical industry ecosystem helps North America dominate the anti-infective agents market.

Competitive Landscape

The competitive landscape in the anti-infective agents market is dynamic and evolving, driven by changing customer preferences, technological advancements, and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the anti-infective agents market include:

Pfizer, Inc., Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc., Bayer Healthcare AG, AstraZeneca Plc., Boehringer Ingelheim, Novartis AG, Astellas Pharma, Inc., GlaxoSmithKline Plc., Alcon Pharmaceuticals Ltd.

Latest Developments

In February 2024, a novel antifungal drug developed by Gilead Sciences, Inc. was approved by the FDA to treat an uncommon and potentially fatal fungal infection. Its repertoire of anti-infective medicines is expanded by this approval.

In August 2023, in order to treat respiratory syncytial virus (RSV) infection in newborns, Merck & Co., Inc. recently reported positive Phase 3 trial results for its experimental antiviral medication. There may be a new therapeutic option in this area thanks to this development.

1. INTRODUCTION OF GLOBAL ANTI-INFECTIVE AGENTS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4. GLOBAL ANTI-INFECTIVE AGENTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.2 Porters Five Force Model
4.3 Value Chain Analysis

5. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY PRODUCT

5.1 Overview
5.2 Antibacterial Drugs
5.3 Antifungal Drugs
5.4 Antiviral Drugs
5.5 Antiparasitic

6. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY ROUTE OF ADMINISTRATION

6.1 Overview
6.2 Oral
6.3 Topical
6.4 Parenteral
6.5 Inhalation

7. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY APPLICATION

7.1 Overview
7.2 Hospital Acquired Infections (HAIs)
7.3 Sexually Transmitted Infections (STIs)
7.4 Community-acquired Infections

8. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY END-USERS

8.1 Overview
8.2 Hospital & Clinic
8.3 Homecare Settings
8.4 Research Institutes

9. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10. GLOBAL ANTI-INFECTIVE AGENTS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11. COMPANY PROFILES

11.1 Pfizer, Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Abbott Laboratories
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Gilead Sciences, Inc.
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Denso Corporation
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Bristol-Myers Squibb Co.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Merck & Co., Inc.
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Bayer Healthcare AG
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 AstraZeneca Plc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Boehringer Ingelheim
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Novartis AG
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments